vs
Side-by-side financial comparison of T Stamp Inc (IDAI) and RELMADA THERAPEUTICS, INC. (RLMD). Click either name above to swap in a different company.
RELMADA THERAPEUTICS, INC. is the larger business by last-quarter revenue ($1.3M vs $908.9K, roughly 1.4× T Stamp Inc). On growth, RELMADA THERAPEUTICS, INC. posted the faster year-over-year revenue change (13.0% vs -39.3%). Over the past eight quarters, RELMADA THERAPEUTICS, INC.'s revenue compounded faster (95.4% CAGR vs 25.9%).
T Stamp Inc, trading under ticker IDAI, develops AI-powered identity verification, trust scoring, and fraud prevention solutions. It serves clients across fintech, healthcare, and e-commerce segments, primarily operating in North America to help organizations securely authenticate user identities and mitigate fraud risks.
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies for central nervous system disorders. Its lead product candidate targets treatment-resistant depression, with ongoing clinical trials to address unmet medical needs in its primary markets of North America and Europe.
IDAI vs RLMD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2023
| Metric | | |
|---|---|---|
| Revenue | $908.9K | $1.3M |
| Net Profit | $-2.5M | — |
| Gross Margin | — | — |
| Operating Margin | -224.9% | -2130.6% |
| Net Margin | -279.9% | — |
| Revenue YoY | -39.3% | 13.0% |
| Net Profit YoY | 57.7% | — |
| EPS (diluted) | $-0.37 | $-0.84 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $908.9K | — | ||
| Q3 25 | $872.5K | — | ||
| Q2 25 | $812.7K | — | ||
| Q1 25 | $545.5K | — | ||
| Q4 24 | $1.5M | — | ||
| Q3 24 | $511.1K | — | ||
| Q2 24 | $500.4K | — | ||
| Q1 24 | $573.7K | — |
| Q4 25 | $-2.5M | — | ||
| Q3 25 | $-1.9M | — | ||
| Q2 25 | $-1.7M | — | ||
| Q1 25 | $-2.2M | — | ||
| Q4 24 | $-6.0M | — | ||
| Q3 24 | $-1.3M | — | ||
| Q2 24 | $-2.6M | — | ||
| Q1 24 | $-2.7M | — |
| Q4 25 | -224.9% | — | ||
| Q3 25 | -203.0% | — | ||
| Q2 25 | -207.0% | — | ||
| Q1 25 | -396.5% | — | ||
| Q4 24 | -81.2% | — | ||
| Q3 24 | -523.7% | — | ||
| Q2 24 | -524.7% | — | ||
| Q1 24 | -496.7% | — |
| Q4 25 | -279.9% | — | ||
| Q3 25 | -219.1% | — | ||
| Q2 25 | -210.7% | — | ||
| Q1 25 | -395.5% | — | ||
| Q4 24 | -401.5% | — | ||
| Q3 24 | -245.7% | — | ||
| Q2 24 | -519.3% | — | ||
| Q1 24 | -466.9% | — |
| Q4 25 | $-0.37 | — | ||
| Q3 25 | $-0.72 | — | ||
| Q2 25 | $-0.69 | — | ||
| Q1 25 | $-0.89 | — | ||
| Q4 24 | $-3.14 | — | ||
| Q3 24 | $-1.06 | — | ||
| Q2 24 | $-3.19 | — | ||
| Q1 24 | $-3.97 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.0M | $96.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $8.7M | $85.4M |
| Total Assets | $11.2M | $97.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.0M | — | ||
| Q3 25 | $5.4M | — | ||
| Q2 25 | $292.1K | — | ||
| Q1 25 | $1.1M | — | ||
| Q4 24 | $2.8M | — | ||
| Q3 24 | $598.0K | — | ||
| Q2 24 | $659.5K | — | ||
| Q1 24 | $816.7K | — |
| Q4 25 | $8.7M | — | ||
| Q3 25 | $6.1M | — | ||
| Q2 25 | $2.4M | — | ||
| Q1 25 | $4.1M | — | ||
| Q4 24 | $3.0M | — | ||
| Q3 24 | $5.4M | — | ||
| Q2 24 | $750.4K | — | ||
| Q1 24 | $1.4M | — |
| Q4 25 | $11.2M | — | ||
| Q3 25 | $11.2M | — | ||
| Q2 25 | $5.7M | — | ||
| Q1 25 | $6.6M | — | ||
| Q4 24 | $8.6M | — | ||
| Q3 24 | $10.6M | — | ||
| Q2 24 | $5.2M | — | ||
| Q1 24 | $5.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $-10.2M |
| Free Cash FlowOCF − Capex | $2.0M | — |
| FCF MarginFCF / Revenue | 215.4% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-5.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | — | ||
| Q3 25 | $-4.0M | — | ||
| Q2 25 | $-2.1M | — | ||
| Q1 25 | $-1.5M | — | ||
| Q4 24 | $-2.7M | — | ||
| Q3 24 | $-2.4M | — | ||
| Q2 24 | $-1.6M | — | ||
| Q1 24 | $-2.2M | — |
| Q4 25 | $2.0M | — | ||
| Q3 25 | $-4.0M | — | ||
| Q2 25 | $-2.1M | — | ||
| Q1 25 | $-1.6M | — | ||
| Q4 24 | $-2.7M | — | ||
| Q3 24 | $-2.4M | — | ||
| Q2 24 | $-1.6M | — | ||
| Q1 24 | $-2.2M | — |
| Q4 25 | 215.4% | — | ||
| Q3 25 | -459.6% | — | ||
| Q2 25 | -258.6% | — | ||
| Q1 25 | -289.2% | — | ||
| Q4 24 | -182.9% | — | ||
| Q3 24 | -475.4% | — | ||
| Q2 24 | -320.9% | — | ||
| Q1 24 | -376.6% | — |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 6.8% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | 0.5% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
